Misty Jenkins AO Profile
Misty Jenkins AO

@DrMistyJenkins

Followers
4K
Following
8K
Media
206
Statuses
2K

Scientist @WEHI_research | Cancer Research | Immunologist | #JenkinsLab | Board director | Speaker | #100WOI |Gunditjmara | #WomeninSTEM #IndigiSTEM She/Her

Melbourne, Victoria
Joined September 2015
Don't wanna be here? Send us removal request.
@DrMistyJenkins
Misty Jenkins AO
2 years
I was honoured as an Officer of the Order of Australia (AO) at government house this week, in esteemed company! @WEHI_research @Prof_G_McArthur Jane Gunn @UniMelbMDHS Jane Hemstrich @Kate_Jenkins_ It takes a village & I am grateful to my family, mentors & colleagues for support
18
9
237
@mscienceaustnz
Millennium Science
1 year
Two big🧠🥼🧠🥼in one 🛩️! Introducing Big Brains in Small Planes - our new video series. 👏Shout out to @DrMistyJenkins (@WEHI_research) for being our inaugural guest. #BBISP #ASI2024SYD @ASImmunology #scicomm
0
4
10
@DrMistyJenkins
Misty Jenkins AO
1 year
Wonderful to see this important #CART cell therapy study published, offering hope for this devastating disease #dipg Congratulations @michelle_monje and team!
@michelle_monje
Michelle Monje🎗️ 🟦
1 year
1/ This is the next chapter of a story about courageous patients and their families, of multidisciplinary teamwork, and hard-fought steps forward to effective therapy for #DIPG #DMG, a universally lethal cancer of the brain and spinal cord. 🧵 https://t.co/hMe0XYplKz
0
1
11
@DrMistyJenkins
Misty Jenkins AO
1 year
I'm tackling the world’s toughest half marathon, the #PointToPinnacle2024, to fund vital brain cancer research at @BrainCancerCtr. Your support fuels breakthroughs & hope for patients. Every step counts! 🏃‍♀️💪 Donate here:
Tweet card summary image
pointtopinnacle2024.grassrootz.com
0
1
16
@DrMistyJenkins
Misty Jenkins AO
1 year
What a brilliant EANO NeuroOncology Conference in Glasgow -an incredible experience! Inspiring presentations & discussions, plus seeing the @BrainCancerCtr and @Markhughesfdn represented on the global stage. Big thanks to the organisers! @braincancerlab @WEHI_research #EANO2024
0
2
28
@DrMistyJenkins
Misty Jenkins AO
1 year
Thanks @kamila_marzec for your excellent organising of a terrific conference!
0
0
13
@BrainCancerCtr
BrainCancerCentre
1 year
Thanks so much to one of our BCC family and Consumer Group members Sarah Kelly for her advocacy in raising awareness and the urgent need for increased funding to brain cancer research. Thanks to Sarah’s incredible efforts, we were thrilled to welcome an engaged group of MPs to
0
2
11
@jitcancer
Journal for ImmunoTherapy of Cancer
1 year
Here’s a closer look at “EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses by @leesa_lerts, Melinda Iliopoulos, Stacie S. Wang, Sarah J. McArthur, @lisamebert, @dralexdav, @drendersby, @auscancadoc, Katharine J.
1
5
11
@DrMistyJenkins
Misty Jenkins AO
1 year
This work can only happen with support from our generous funders including @nhmrc @BrainCancerCtr @carriesB4BC @_IsabellaMarcus @_RCDFoundation @VPCCresearch @BickmoreCarrie #CARTcells #braincancer #immunotherapy
0
0
8
@DrMistyJenkins
Misty Jenkins AO
1 year
0
1
6
@DrMistyJenkins
Misty Jenkins AO
1 year
This preclinical data shows the robust efficacy of EphA3-targeted CAR T cells and provides evidence of long-term persistence and ability to protect against a second tumour challenge. Clinical trials will be required to determine the real-world benefits of this treatment.
1
1
8
@DrMistyJenkins
Misty Jenkins AO
1 year
These mice achieved complete tumour clearance and maintained this response six months following treatment.
1
0
2
@DrMistyJenkins
Misty Jenkins AO
1 year
CAR T cells remained detectable in the peripheral blood of long-term survivors 9 weeks post-treatment with the EphA3-targeted CAR T cells. Long-term survivors were rechallenged intracranially with a second tumour to assess the remaining CAR T cells' functional capacity.
1
0
1
@DrMistyJenkins
Misty Jenkins AO
1 year
1
0
2
@DrMistyJenkins
Misty Jenkins AO
1 year
This robust anti-tumour effect was also observed in an adult glioblastoma mouse model, with mice exhibiting tumour eradication within four weeks post-treatment. This led to a sustained complete response and significant survival benefit over controls.
1
0
2
@DrMistyJenkins
Misty Jenkins AO
1 year
In a xenograft mouse model, these human EphA3-targeted CAR T cells were effective against paediatric diffuse midline gliomas.
1
0
2
@DrMistyJenkins
Misty Jenkins AO
1 year
The second-generation EphA3-targeted CAR T cell demonstrated antigen-specific cytotoxicity and cytokine production against high-grade glioma models using in vitro assays.
1
0
2
@DrMistyJenkins
Misty Jenkins AO
1 year
Ephrin-type A receptor 3, EphA3, was identified as a prevalently expressed target across glioma patient samples via cell surface proteomics of primary samples and RNA sequencing data obtained via public databases.
1
0
2
@DrMistyJenkins
Misty Jenkins AO
1 year
We performed cell surface proteomics of adult and paediatric brain cancer patient samples to identify abundant and widely expressed antigens. We identified EphA3 as a suitable target and developed a novel EphA3-targeted CAR T cell treatment for brain cancer.
1
0
2
@DrMistyJenkins
Misty Jenkins AO
1 year
High-grade brain cancers remain lethal as current treatments offer limited efficacy. Chimeric Antigen Receptor (CAR) T cell therapies are a promising strategy to address this. However, selecting the optimal antigen remains challenging in achieving long-term clinical outcomes.
1
0
2
@DrMistyJenkins
Misty Jenkins AO
1 year
1
0
2